Clinical Trials in Detroit

Showing 5041-5060 of 19,719 trials

A Provider Intervention to Reduce Financial Toxicity in Patients With Cancer Through Improved Treatment Cost Discussions

NCT07042191

The overall goal of this research program is to address financial toxicity through the development, testing, and implementation of a multi-level communication intervention. If successful, this intervention could be a companion intervention for Cancer providers in combination with the already in testing DISCO app (Discussions of Cost App) for patients. Participants will: * complete a baseline survey * attend two one on one meetings, one as part of the development and the second as part of the pilot testing of the intervention.

HealthyFinancial Toxicity

Barbara Ann Karmanos Cancer Institute20 participantsStarted Dec 2022

Detroit, Michigan, United States

COMPLETEDNA36 miles

Comparing the Effects of Exercise on the Structure and Function of Fat Tissue

NCT05328570

Assess differences in structure and biological function of abdominal subcutaneous adipose tissue samples collected from adults who exercise regularly vs. a well-matched cohort of non-exercisers.

Adiposity

University of Michigan45 participantsStarted Jun 2020

Ann Arbor, Michigan, United States

RECRUITINGPhase 353 miles

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451

The purpose of this trial is: 1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to \< 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines 2. to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment 3. to collect safety data in this population for up to three years after the last dose of study treatment

Chronic Spontaneous Urticaria

Novartis Pharmaceuticals100 participantsStarted Jul 2023

Bakersfield, California, United States • San Diego, California, United States • Coral Gables, Florida, United States +60 more locations

A Provider Intervention to Reduce Financial Toxicity in Patients With Cancer Through Improved Treatment Cost Discussions

Comparing the Effects of Exercise on the Structure and Function of Fat Tissue

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Find Trials by Condition in Detroit

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

Beacon Sensors and Telerehabilitation for Low Vision

LTFU for All Cell and Gene Therapy Studies

Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial

Cough Reduction in IPF With Nalbuphine ER

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Adolescent Master Protocol

Gluten Technology and Education for Celiac Health

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Depression Trial)

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics